# A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

> **NCT01840943** · PHASE3 · TERMINATED · sponsor: **Xian-Janssen Pharmaceutical Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** CAELYX
- **DRUG:** Topotecan HCl

## Key facts

- **NCT ID:** NCT01840943
- **Lead sponsor:** Xian-Janssen Pharmaceutical Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-06
- **Primary completion:** 2014-05
- **Final completion:** 2014-08
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** the study was terminated due to medication supply issue from current manufacturer
- **Last updated:** 2015-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01840943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01840943, "A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01840943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*